Navigation Links
Lexicon Initiates Phase 2 Clinical Trial of LX2931 in Patients With Rheumatoid Arthritis
Date:8/4/2009

eased the inflammatory response in multiple models of arthritis, inflammation and transplantation.

The Phase 2 clinical trial is designed as a 12-week, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of LX2931 and its effects on symptoms associated with rheumatoid arthritis. The study will include multiple centers in the United States and Eastern Europe. The company expects to enroll up to 120 patients with rheumatoid arthritis on stable methotrexate therapy. Three dose levels will be evaluated: a 70 mg dose, a 110 mg dose and a 150 mg dose, each administered once daily. The primary endpoint will be the ACR20, which is defined by the American College of Rheumatology (ACR) as a 20 percent improvement in symptoms associated with rheumatoid arthritis. Multiple secondary endpoints will also be evaluated, including ACR50, ACR70 and DAS28.

In addition to LX2931, Lexicon has two other drug candidates progressing in Phase 2 clinical trials, LX1031 for irritable bowel syndrome and LX1032 for carcinoid syndrome. Furthermore, LX4211 for diabetes has recently completed dosing in a Phase 1 clinical trial. For more information about Lexicon's clinical development programs, please visit www.lexpharma.com.

About Rheumatoid Arthritis

Lymphocytes are a type of white blood cell that play an important role in the immune system. Inappropriate activation of lymphocytes is often associated with autoimmune diseases, a spectrum of disorders in which the immune system malfunctions and causes the body to attack its own organs, tissues and cells. Rheumatoid arthritis is an autoimmune disorder characterized by stiffness, pain, swelling, and limitation of motion in multiple joints. More than 2 million Americans suffer from rheumatoid arthritis, which, if left untreated, can result in disfigurement and disabilit
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results
2. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
3. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
4. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
5. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
6. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
7. Harbinger Research Initiates Coverage on HearAtLast
8. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
9. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
10. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
11. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... New findings released today from a poll conducted ... people diagnosed with a brain tumor needed more information ... at the time of diagnosis, and had only a ... course of treatment. The release of these findings corresponds ... volunteer network, the ABTA CommYOUnity™, dedicated to serving the ...
(Date:5/4/2015)... May 04, 2015 Pricing Healthcare ... $3,000) of one patient receiving care at St. George ... The procedure must be performed by July 15th, 2015, and ... in full up front and forego the filing of insurance ... economically burdensome every year, and it devastates more and more ...
(Date:5/4/2015)... New York, NY (PRWEB) May 04, 2015 ... Mother Hale Learning Center from Hale House. The Mother ... by offering high-quality, affordable Early Childhood Education. Sheltering Arms ... families will continue to be served by the center. ... serves 45 children ages six weeks to five years, ...
(Date:5/4/2015)... Helena, MT (PRWEB) May 04, 2015 ... partnered with Care to Care, LLC to manage outpatient ... will help New West Medicare ensure its members are ... avoid unnecessary radiation. , Working closely with New West ... in promoting the safe use of advanced imaging and ...
(Date:5/4/2015)... Elisabeth Rosenthal’s article* on “balance billing” ... the healthcare fraternity as well as patients about ... of balance billing. In definition, balance billing is ... patient for the difference between what the patient's ... provider chooses to charge. Rosenthal’s article talks about ...
Breaking Medicine News(10 mins):Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 2Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 3Health News:Sheltering Arms Acquires the Mother Hale Learning Center 2Health News:New West Medicare Partners with Care to Care, LLC to Manage Advanced Imaging Services 2Health News:Out of Network Balance Billing Without Being Viewed as Fraud 2Health News:Out of Network Balance Billing Without Being Viewed as Fraud 3
... in US have come up with a heady option that ... in brain cells often after an episode of stroke or ... John Hopkins University ,who conducted a study on mice, ... the skin of red grapes, administered in moderate doses, showed ...
... overweight youngsters lose weight by concentrating on the way they ... make them// gorge even more, according to a recent study. ... motivated to change their eating habits than those who are ... suggest that getting children of all shapes and sizes to ...
... report released, based on the study conducted by epidemiologists ... significant increase in mortality risk among the workers at// ... perfluorooctanoic acid, the key component of the material Teflon. ... company definitely reveals lower mortality rates than West ...
... fever in Kerala will not affect the state's booming tourism ... ,"As the World Health Organisation (WHO) has come out with ... chikungunya, things have cheered up. There have been no reports ... to Kerala," Balakrishnan told reporters here. ,The fever, ...
... despite the fact that few actually need it, says a ... stay healthy is a balanced diet. ,People are often ... fewer nutrients than it used to, said Jane Clarke. The ... reported the online edition of Daily Mail. ...
... Treatment outcomes vary widely and depend on which state, ... the finding of a new report//. ,The report, ... have a 69 percent lower risk of dying at ... the difference between the best- and worst-performing hospitals has ...
Cached Medicine News:Health News:Obese Kids Unmotivated byWeight Loss campaigns 2Health News:Madhya Pradesh Tops in Implementing Child Health Scheme 2Health News:Hospital Outcome Linked to its Quality 2
(Date:5/4/2015)... WHIPPANY, N.J. , May 4, 2015 ... agreement with Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... clinical development for the prevention of thrombosis. Under the ... in areas of high unmet medical need. As ... evaluate the therapeutic profile of ISIS-FXI Rx in ...
(Date:5/4/2015)... BUFFALO, N.Y. , May 4, 2015 /PRNewswire/ ... Stephanie Englert , PharmD, has completed preliminary analysis ... Disorder and Schizophrenia. Resources from Clinical Support Services, ... Medication Reviews (CMR) with patients currently taking psychiatric ... events. The research found that 93% of patients ...
(Date:5/4/2015)... , May 4, 2015 MEI Pharma, ... focused on the clinical development of novel therapies ... mitochondria-specific effects of the Company,s investigational drug candidate ... activity when combined with a tyrosine-kinase inhibitor (TKI). ... to be a potent inhibitor of mitochondrial oxidative ...
Breaking Medicine Technology:Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 2Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5
This portable resource provides definitions for medical acronyms and abbreviations....
Stedman's Medical Dictionary includes charts and tables and navigation and search tools....
With Skyscape's smARTlink technology, Tabers can cross-index with other clinical and drug prescription products from Skyscape to provide an integrated source of clinical information....
CPTMeister is a coding reference based on the Physicians' Current Procedural Terminology (CPT) codes developed by the American Medical Association. It is an iSilo document composed of more than 2,000...
Medicine Products: